Dihydrouracil Dehydrogenase (NADP)
"Dihydrouracil Dehydrogenase (NADP)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxidoreductase involved in pyrimidine base degradation. It catalyzes the catabolism of THYMINE; URACIL and the chemotherapeutic drug, 5-FLUOROURACIL.
| Descriptor ID |
D042943
|
| MeSH Number(s) |
D08.811.682.660.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dihydrouracil Dehydrogenase (NADP)".
Below are MeSH descriptors whose meaning is more specific than "Dihydrouracil Dehydrogenase (NADP)".
This graph shows the total number of publications written about "Dihydrouracil Dehydrogenase (NADP)" by people in this website by year, and whether "Dihydrouracil Dehydrogenase (NADP)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dihydrouracil Dehydrogenase (NADP)" by people in Profiles.
-
Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Mol Nutr Food Res. 2014 Oct; 58(10):2023-35.
-
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol. 2010 Oct 20; 28(30):4554-61.
-
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Expert Opin Drug Saf. 2009 Sep; 8(5):507-14.
-
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006 Nov 20; 24(33):5313-27.
-
Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep. 2004 Jan; 11(1):9-15.
-
UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review. Int J Cancer. 2001 Feb 20; 96(1):1-10.
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.